He felt healthy but routine blood tests revealed declining kidney function. His case highlights the silent progression of ...

AstraZeneca AZN announced that the FDA has approved its blockbuster rare disease drug, Ultomiris (ravulizumab), for reducing ...

Vera Therapeutics (NASDAQ:VERA) reported final efficacy results from its Phase III ORIGIN trial evaluating atacicept, ...

A central Arkansas father is fighting for his life and hoping a stranger could be the answer to his prayers as he searches ...

Annualized eGFR slope of -0.6 vs. -5.7 mL/min/1.73 m²/year for placebo, a 5.1 mL/min/1.73 m²/year treatment difference (p<0.001)89% and 81% ...

AstraZeneca (NYSE: AZN) announced the US availability of Zegfrovy (sunvozertinib), a treatment for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth ...

Vera Therapeutics (Nasdaq: VERA) announced that the final efficacy analysis of its ORIGIN 3 trial for TRUTAKNA (atacicept-vymj) in adults with primary IgA nephropathy (IgAN) met statistical ...

With a late Thursday nod from the FDA to reduce protein levels in the urine of patients with primary immunoglobulin A ...

Sparsentan lowered blood pressure more than irbesartan at week 8, with mean differences of -7.2 mmHg systolic and -5.6 mmHg diastolic.

ZEGFROVY is now available in the US for post-platinum EGFR exon 20 insertion NSCLC after a 46% response rate in WU-KONG1B.

DOVER, DE / ACCESS Newswire /3, 2026 / Healz (healz.ai) is a platform for getting a cancer second opinion online. It brings ...

Accelerated approval is supported by 34-week interim data from the phase 3 I CAN trial showing a statistically significant 43% placebo-adjusted reduction in proteinuria.